Adductor Canal Nerve Block Following Total Knee Arthroplasty
|ClinicalTrials.gov Identifier: NCT01939379|
Recruitment Status : Terminated
First Posted : September 11, 2013
Last Update Posted : March 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Post-op Pain||Drug: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed. Drug: For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Adductor Canal Nerve Block Following Total Knee Arthroplasty: A Randomized, Prospective Study Comparing High vs. Low Volume Bolus of 0.33% Ropivacaine|
|Study Start Date :||September 2013|
|Actual Primary Completion Date :||July 25, 2017|
|Actual Study Completion Date :||July 25, 2017|
Active Comparator: 15ml ropivacaine
Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
Drug: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.
Active Comparator: 30ml ropivacaine
If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
Drug: For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.
- Total Opiate pain medication [ Time Frame: The total amount of opiate pain medication will be recorded at 6 hour intervals for 48 hours after surgery. ]At the end of the 48 hours period the total opiate pain medication taken will be collected and used for comparison as our primary outcome
- Patient satisfaction with pain control [ Time Frame: We will look at the secondary outcome measure beginning every six hours for 48 hours after surgery ]Secondary outcome measures will include demographic characteristics, pain scores, medication administration,patient satisfaction with pain control and any complications that may have arisen. We will also record the location of the adductor canal catheter on the final bolus dose.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01939379
|United States, California|
|Loma Linda University Medical Center East Campus Hospital|
|Loma Linda, California, United States, 92354|